Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Coherus Oncology Inc (NASDAQ: CHRS) closed at $1.76 in the last session, up 2.92% from day before closing price of $1.71. In other words, the price has increased by $2.92 from its previous closing price. On the day, 1.07 million shares were traded. CHRS stock price reached its highest trading level at $1.78 during the session, while it also had its lowest trading level at $1.69.
Ratios:
We take a closer look at CHRS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.43 and its Current Ratio is at 1.44. In the meantime, Its Debt-to-Equity ratio is 0.45 whereas as Long-Term Debt/Eq ratio is at 0.44.
On August 16, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $4 to $1.50.
On November 17, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $11.Robert W. Baird initiated its Outperform rating on November 17, 2023, with a $11 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 23 ’25 when Wahlstrom Mats sold 99,988 shares for $0.74 per share. The transaction valued at 73,881 led to the insider holds 0 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CHRS now has a Market Capitalization of 204560000 and an Enterprise Value of 7952004. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.43 while its Price-to-Book (P/B) ratio in mrq is 1.71. Its current Enterprise Value per Revenue stands at 0.029 whereas that against EBITDA is -0.095.
Stock Price History:
The Beta on a monthly basis for CHRS is 0.96, which has changed by 0.8125644 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, CHRS has reached a high of $2.43, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is 38.95%, while the 200-Day Moving Average is calculated to be 63.25%.
Shares Statistics:
According to the various share statistics, CHRS traded on average about 1.36M shares per day over the past 3-months and 1210760 shares per day over the past 10 days. A total of 116.22M shares are outstanding, with a floating share count of 105.68M. Insiders hold about 9.07% of the company’s shares, while institutions hold 46.81% stake in the company. Shares short for CHRS as of 1757894400 were 31866663 with a Short Ratio of 23.47, compared to 1755216000 on 32727800. Therefore, it implies a Short% of Shares Outstanding of 31866663 and a Short% of Float of 28.51.
Earnings Estimates
As of right now, 2.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.12 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$1.31 and -$1.31 for the fiscal current year, implying an average EPS of -$1.31. EPS for the following year is -$0.79, with 2.0 analysts recommending between -$0.44 and -$1.13.
Revenue Estimates
According to 5 analysts,. The current quarter’s revenue is expected to be $13.41M. It ranges from a high estimate of $15M to a low estimate of $12M. As of. The current estimate, Coherus Oncology Inc’s year-ago sales were $70.77MFor the next quarter, 5 analysts are estimating revenue of $15.76M. There is a high estimate of $17.57M for the next quarter, whereas the lowest estimate is $12M.
A total of 4 analysts have provided revenue estimates for CHRS’s current fiscal year. The highest revenue estimate was $49.2M, while the lowest revenue estimate was $42.02M, resulting in an average revenue estimate of $46.27M. In the same quarter a year ago, actual revenue was $266.96MBased on 5 analysts’ estimates, the company’s revenue will be $96.91M in the next fiscal year. The high estimate is $161.64M and the low estimate is $61.94M.
